Genitope Corporation (Nasdaq: GTOP)’s independent Data Safety Monitoring Board (DSMB) has recommended after a review, that the company’s pivotal Phase 3 clinical trial of MyVax® for treatment of follicular non-Hodgkin's Lymphoma (fNHL) should go ahead as planned.
The trial which is expected to finish in December 2007 is evaluating the safety and efficacy of MyVax® (the company’s lead product candidate) personalized immunotherapy in patients with previously untreated fNHL and compares this to a nonspecific immunotherapy control.
MyVax® personalized immunotherapy is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells.
Read the full press release.
.jpg)
Comment Preview